Character Biosciences

• 27/03/2025
• Series B
• $39,000,000

Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology. Our mission is to identify the genetic and molecular drivers of disease progression so we can develop targeted therapies for patients who urgently need them.

We've built one of the most comprehensive resources in age-related eye diseases by partnering with over 150 ophthalmology clinics to integrate genetics with longitudinal clinical and imaging data. This deep phenotyping approach enables us to reclassify complex diseases like age-related macular degeneration (AMD) into genetically defined subtypes, unlocking novel therapeutic targets and optimizing patient selection for clinical trials.

Character Bio’s AI-powered platform combines genomics, multi-modal data, and machine learning to discover and develop therapies that are more precise and more effective. Our lead programs, CTX114 and CTX203, are advancing toward clinical trials and are designed to slow or prevent vision loss in AMD patients.

We are committed to delivering a new generation of precision medicines to treat and ultimately cure age-related blindness.

---

---